« Return to News | Drug Sponsors

Spectrum Pharmaceuticals acquires Talon Therapeutics

Wednesday, July 17, 2013 03:46 PM

Spectrum Pharmaceuticals, a commercial and drug development biotech company with a primary focus in hematology and oncology, will acquire Talon Therapeutics, a biopharmaceutical company based in South San Francisco, Calif.

Spectrum will pay Talon stockholders approximately $11.3 million in cash and will issue three million shares of its common stock in exchange for the cancellation of all outstanding indebtedness under Talon's credit facility.

Spectrum will gain worldwide rights to Marqibo, an FDA-approved hematology product for the treatment of leukemia, as well as phase II product Menadione Topical Lotion for the treatment of the skin toxicity associated with epidermal growth factor receptor anti-cancer agents, such as ERBITUX. Marqibo is a novel, sphingomyelin-based liposome encapsulated formulation of vincristine indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Vincristine, a microtubule inhibitor, is used in combination regimens for treatment of adult and pediatric hematologic and solid tumor malignancies.

Talon stockholders will also receive contingent value rights up to $195 million in future cash payments from Spectrum upon the achievement of milestones for Marqibo and an approval-based milestone for Menadione Topical Lotion.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.